Letter by Brocco et al Regarding Article, "Percutaneous Treatment With Drug-Eluting Stent Implantation Versus Bypass Surgery for Unprotected Left Main Stenosis: A Single-Center Experience"
To the Editor:
Statistical significance and clinical relevance are important and different issues in reporting and interpreting results of studies that aim to compare 2 or more groups of subjects. Statistical significance refers to the probability that the differences between 2 or more groups occur by chance; usually it is expressed as probability value with an arbitrary cutoff at the value of 0.05. Clinical relevance refers to the magnitude of the differences, and it is usually presented as a measure of effect or impact or simply in the form of differences of means or proportions. Sometimes clinical relevance and statistical significance are conflicting: A difference between 2 groups may be statistically significant but clinically irrelevant or vice versa. A common pitfall is to mistake statistical significance for a measure of clinical relevance: The lower the probability value, the higher the clinical effect; the higher the probability value, the lower the clinical effect.
The article by Chieffo et al, 1 recently published in Circulation, is an example in which the results should be clinically relevant but are statistically not significant. The authors aim to compare percutaneous treatment with drug-eluting stent implantation versus bypass surgery for unprotected left main stenosis. They state in the conclusions, ". . .there is no difference in the degree of protection against death, stroke, myocardial infarction, and revascularization. . ." (p 2545). This conclusion is biased because it ignores 2 important elements. First, the point estimates of the odds ratio both for death and for major adverse cardiovascular and cerebrovascular events (MACCE) at 1 year are far enough from the unit to suggest the presence of an important difference between the treatments. Second, the study population was very small size, with the consequence that the power of the study is low (45% for MACCE, 32% for death; estimates based on data reported in the article).
The clinical relevance of the results of Chieffo et al 1 may be very great: We can estimate a number needed to treat at about 8 to avoid a MACCE at 1 year, an impact rarely reported. Therefore, we think that the low power of the study should be considered in the conclusions and should be emphasized in the limitations of the study and in the accompanying editorial. 2
